|Daily Range||$9.21 - $9.52|
|52-Week Range||$8.54 - $29.83|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||443,230|
|Current FY EPS||-$2.85|
ONCOMED PHARMACEUTICALS INC (OMED) Description
ONCOMED PHARMACEUTICALS INC Website: http://www.oncomed.com/
Rising R&D expenses and slowing Revlimid growth may have caused Celgene to come up short in Q4, but Wall Street appears to have missed something even bigger.
The biotech's shares sank after independent investigators reported that the company's experimental pancreatic cancer drug appears destined to miss its study goals in an ongoing midstage trial.
Celgene outperformed the broader market in 2015, but can the company deliver superior results once more in 2016?
Celgene's presentation at the Super Bowl of all healthcare conferences on Monday unearthed plenty of must-know information for investors.